Prelude Therapeutics Investor Presentation — May 2021

Document content

Corporate Presentation

May 20212Disclaimer

This presentation contains“forward -looking” statements within themeaning ofthe“safeharbor” provisions ofthePrivate Securities Litigation

Reform Actof1995 ,including, butnotlimited to:ourplans todevelop andcommercialize small molecule therapies, ourexpectations about timing

andability tocommence, enroll orcomplete clinical studies andtoobtain regulatory approvals forPRT543,PRT811,PRT1419 ,PRT2527 and

other candidates indevelopment, theability ofourproduct candidates totreat various cancers, theability todiscover additional suitable

candidates forregulatory approval, thepotential impact oftheCOVID -19pandemic andthesufficiency ofourcash andcash equivalents tofund

Anystatements contained herein orprovided orally thatarenotstatements ofhistorical factmay bedeemed tobeforward -looking statements .In

some cases, youcanidentify forward -looking statements bysuch terminology as‘‘believe,’’‘‘may,’’‘‘will,’’‘‘potentially,’’ ‘‘estimate,’’ ‘‘continue,’’

‘‘anticipate,’’ ‘‘intend,’’‘‘could,’’‘‘would,’’‘‘project,’’‘‘plan,’’‘‘expect’’ andsimilar expressions thatconvey uncertainty offuture events oroutcomes,

although notallforward -looking statements contain these words .Statements, including forward -looking statements, speak only tothedate they

areprovided (unless anearlier date isindicated) .

These forward -looking statements arebased onthebeliefs ofourmanagement aswell asassumptions made byand information currently

available tous.Although webelieve theexpectations reflected insuch forward -looking statements arereasonable, wecangive noassurance that

such expectations willprove tobecorrect .Ifsuch assumptions donotfullymaterialize orprove incorrect, theevents orcircumstances referred to

intheforward -looking statements may notoccur .Weundertake noobligation toupdate publicly anyforward -looking statements foranyreason

after thedate ofthispresentation toconform these statements toactual results ortochanges inourexpectations, except asrequired bylaw.

Accordingly, readers arecautioned nottoplace undue reliance onthese forward -looking statements .Additional risks anduncertainties thatcould

affect ourbusiness areincluded under thecaption“RiskFactors” inourQuarterly Report onForm 10-Qfiled with theSecurities andExchange

Commission forthethree months ended March 31,2021 .Powered by scientists with a

track record of delivering

precision oncology medicinesDiscovery Engine

Rapidly advancing potentially high

value therapy candidates with a

commitment to future patient

access, awareness, and supportCommercial Approach